MedTrace Logo

A Single Dose Study to Evaluate the Pharmacokinetics of Acoramidis Modified Release Formulations in Healthy Subjects

NCT04769479 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-09-19

No results posted yet for this study

Summary

This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.

Conditions

  • Amyloidosis

Interventions

DRUG

acoramidis

acoramidis

Sponsors & Collaborators

  • Eidos Therapeutics, a BridgeBio company

    lead INDUSTRY

Principal Investigators

  • Philip Evans, MBChB, MRCS · Quotient Sciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-28
Primary Completion
2021-08-04
Completion
2021-09-03

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04769479 on ClinicalTrials.gov